Datahug: Oncology Drug Discovery Platform
Datahug supports pharmaceutical and biotech companies in the drug discovery process using digital twins. It is designed for organizations requiring a compliant pipeline from data ingestion to regulatory submission.
At a glance
- Category
- Healthcare
- Best for
- Pharmaceutical companies, Biotechnology firms, Contract Research Organizations (CROs), Oncology research institutions
- Pricing
- Pricing was not clearly available from the provided evidence. Buyers should confirm current pricing on the vendor website.
- Key use cases
- Digital Twin Simulation, Regulatory Submission Preparation, Patient Cohort Modeling, Drug Candidate Scoring
- Official website
- datahug.ai
Datahug is a platform designed for oncology drug discovery. It uses a digital twin approach to simulate molecules, biomarkers, and cohorts before wet-lab testing, which may help reduce costs and timelines associated with traditional R&D.
The tool is intended for pharmaceutical companies, biotech firms, and research organizations such as CROs. It uses AI for scoring candidates, quantum computing for validation, and blockchain to maintain a record of data provenance.
Key capabilities include the creation of oncology data vaults and the generation of synthetic datasets that align with regulatory requirements. The platform is designed to support workflows that lead toward FDA and EMA submissions.
Buyers should confirm how the platform's technical requirements align with their internal team's expertise and verify that the automated documentation meets their specific regulatory needs.
Key Features
An oncology-specific data vault for storing and managing research data.
A cohort builder used to create synthetic, regulatory-aligned datasets for study design.
A GenAI tool used for scoring drug candidates and generating hypotheses.
Provides cryptographic hashing and time-stamping for data immutability and provenance.
A layer designed to verify AI-driven predictions using physics-based validation.
Automates validation and documentation to support FDA and EMA submission readiness.
Use Cases
Simulating molecules and compounds in a digital environment before starting wet-lab experiments.
Using an automated pipeline to move from raw data ingestion to eCTD documentation.
Building synthetic cohorts to explore patient variability while protecting privacy.
Applying GenAI to score and prioritize therapeutic targets and compounds.
Best For
Pricing
Pricing was not clearly available from the provided evidence. Buyers should confirm current pricing on the vendor website.
FAQ
Datahug is used for oncology drug discovery by creating digital twins of molecules and cohorts, which allows for simulation and AI-driven scoring before lab testing.
The platform is designed for FDA/EMA readiness and supports HIPAA, GDPR, and 21 CFR Part 11 compliance.
It is designed for pharmaceutical companies, biotechnology companies, and hospitals or CROs managing oncology data and drug pipelines.
Source category: Healthcare
Source subcategory: Drug Discovery Platform
